Agenda
3:00 PM - 3:30 PM    Registration and Networking
3:30 PM - 5:00 PM    Industry Panel
5:00 PM - 6:30 PM    Networking Reception

From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.

Questions that will be raised include:
• What are the best approaches for identifying a good partner?
• What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A?
• What about the rising of Big Pharma VC Funds?
• What are the strategies for attracting, securing and structuring strategic investments?
• How the Larger Bio-Companies’ needs differ from VCs’ needs?
• What are the key contract terms to be negotiated?
• What are the strategic reasoning behind different kinds partnerships?
• Effects on existing and potential future collaboration partners and other strategic decisions.
• Pros and cons of a small company partnering with a larger company.
• “Dos” and “don’ts” of managing these important relationships.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Speakers | Partial List
• Dr. Jim Schaeffer, Executive Director of Licensing & External Research for Merck Research Laboratories, Merck & Co., Inc.
• Simeon J. George, Partner, US ceedd, GlaxoSmithKline
• Sunil Patel Vice President of Corporate Development, OncoMed Pharmaceuticals
• Lead Moderator: Kurt Mulville, Moderator, Orrick Herrington & Sutcliffe LLP


Cost & Registration
• Regular Price: $50
• Partners' Network: $40
• BioCenter Members: Free (please RSVP to Melissa)
• On-site Registration: add $10 to the above
This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Venue
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»


Speakers Bios

Dr. Jim Schaeffer, Director of Licensing & External Research, Merck Research Laboratories, Merck & Co., Inc.
Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of four major agreements. Jim moved to San Diego in 2004 to assume the role of Merck's "Science Scout" on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the past four years, Jim has been directly involved in the execution of 7 major agreements with West Coast based organizations including recent agreements with AmbrX, Marcadia, MediVas, the Gladstone Institute, the University of California in San Francisco and the University of Texas-Southwestern. As of July 2008, Jim is also responsible for Merck's scouting efforts in China.

Simeon J. George, Partner, SR One, GSK's Centre of Excellence for External Drug Discovery (ceedd)
Simeon joined SR One in 2007. Simeon serves as a member of the Board of Directors of Anaphore and Genocea Biosciences and as an observer at Rib-X and Syntaxin. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. Simeon earned his M.D. degree from the University of Pennsylvania School of Medicine and his M.B.A. degree from the Wharton School of Business, where he was a Mayer Scholar. He holds a B.A. in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa.

^ Back To Top ^

Sunil Patel, Senior Vice President of Corporate Development, OncoMed Pharmaceuticals
Mr. Patel brings more than 15 years of biopharmaceuticals industry experience to his new role at OncoMed. He joins OncoMed from BiPar Sciences where as Vice President, Corporate Development and Marketing he led the sale of that company to Sanofi-Aventis in April of this year. Previously, he held senior corporate development, marketing, and strategy positions with Allos Therapeutics, Connetics Corporation, Abgenix and Gilead Sciences.
Mr. Patel also served as a consultant with McKinsey & Company. Earlier in his career, he was a researcher at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and his master's degree in Molecular Bioengineering/Biotechnology at the University of Washington.

^ Back To Top ^

 

Mark Edwards, Managing Director, Deloitte Recap
Mark G. Edwards is the Managing Director of Recombinant Capital, Inc. (Recap), a consulting firm based in Walnut Creek, California. More than 500 biotechnology, pharmaceutical, and service companies subscribe to Recap?s databases (Recap.com & rDNA.com) or retain Recap to advise them on biotech alliances and valuations. Mr. Edwards has been invited to speak to many trade and industry groups about structuring alliances and other business relationships that are related to the development and commercialization of new technologies, compounds, or products. These groups include the Institute of Medicine, the Licensing Executives Society, the Association of University Technology Managers, Sigma Xi (the Scientific Research Society of the National Academy of Sciences), and the Biotechnology Industry Organization. He has also provided expert testimony at deposition or trial in lawsuits dealing with either reasonable royalties or normal custom and practice in the biotechnology and pharmaceutical industries. Mr. Edwards is on the Board of Directors of Allos Therapeutics, Inc. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford University.

 

Kurt Mulville, Partner, Intellectual Property and Technology Transactions Groups, Emerging Companies Group Member, Orrick, Herrington & Sutcliffe LL
Kurt T. Mulville, a partner in the Orange County office, is a member of the Intellectual Property Group. Mr. Mulville develops patent portfolios for technology companies with emerging technologies, and has extensive experience in patent litigation at the trial and appellate levels. Mr. Mulville specializes in developing successful patent prosecution and litigation strategies in highly competitive environments, such as the fields of biomedical devices and biotechnology.